A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer

Wendy L. Allen1,*, Leanne Stevenson1,*, Vicky M. Coyle1, Puthen V. Jithesh1, Irina Proutski1, Gail Carson1, Michael A Gordon2, Heinz-Josef D Lenz2, Sandra Van Schaeybroeck1, Daniel B. Longley1,Ψ and Patrick G. Johnston1,Ψ

1Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland.

2Division of Medical Oncology, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, California 90033, USA.

*Equal contribution.

ΨEqual contribution.

Running title: SART1 regulates FLIP expression and drug resistance.

Key words: Drug resistance, colorectal cancer, systems biology, caspase 8, c-FLIP

Financial support from Cancer Research UK (C212/A7402); Cancer Research UK Bobby Moore Fellowship, Research and Development Office Northern Ireland, Department of Health, Social Services and Public Safety (RRG/3261/05, RRG 6.42) and Staff Training and Development Unit (STDU), Queen’s University Belfast.

Corresponding author: Daniel B. Longley, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, 97 Lisburn Road, Belfast, BT9 7BL, Northern Ireland, Tel: +44 28 90972764. Fax: +44 28 90972776. E-mail: d.longley@qub.ac.uk
Conflict of interest: P. Johnston is employed by and has an ownership interest in Almac Diagnostics.

Notes: Word count: 4442, number of figures: 6, number of tables: 1
Abstract

Chemotherapy response rates for advanced colorectal cancer remain disappointingly low, primarily due to drug resistance, so there is an urgent need to improve current treatment strategies. In order to identify novel determinants of resistance to the clinically relevant drugs 5-Fluorouracil (5-FU) and SN38 (the active metabolite of irinotecan), transcriptional profiling experiments were carried out on pre-treatment metastatic colorectal cancer biopsies and HCT116 parental and chemotherapy-resistant cell line models using a disease-specific DNA microarray. To enrich for potential chemo-resistance-determining genes, an unsupervised bioinformatics approach was employed, and 50 genes were selected and then functionally assessed using custom-designed siRNA screens. In the primary siRNA screen, silencing of 21 genes sensitised HCT116 cells to either 5-FU or SN38 treatment. Three genes (RAPGEF2, PTRF and SART1) were selected for further analysis in a panel of 7 CRC cell lines. Silencing SART1 sensitised all 7 cell lines to 5-FU treatment and 4/7 cell lines to SN38 treatment. However, silencing of RAPGEF2 or PTRF had no significant effect on 5-FU or SN38 sensitivity in the wider cell line panel. Further functional analysis of SART1 demonstrated that its silencing induced apoptosis that was caspase 8-dependent. Furthermore, silencing of SART1 led to a down-regulation of the caspase 8 inhibitor, c-FLIP, which we have previously demonstrated is a key determinant of drug resistance in colorectal cancer. This study demonstrates the power of systems biology approaches for identifying novel genes that regulate drug resistance and identifies SART1 as a previously unidentified regulator of c-FLIP and drug-induced activation of caspase 8.
Introduction

Resistance to chemotherapeutic drugs is a major problem in the treatment of many cancers. In colorectal cancer (CRC), the long established antimetabolite drug 5-fluorouracil (5-FU), even when used in combination with newer cytotoxic drugs such as oxaliplatin and irinotecan (CPT-11), still produces a response in only 50% of patients with advanced disease (1, 2). Hence, there is a pressing need for research to identify the key, clinically relevant molecular determinants of sensitivity to particular chemotherapy drugs as these may constitute novel predictive biomarkers of drug response and drug resistance. In addition, these key molecular determinants of drug sensitivity may identify novel therapeutic strategies for enhancing the clinical effectiveness of chemotherapy.

Recently, high throughput technologies such as DNA microarrays have been employed to identify panels of markers that predict prognosis (3-8) or response to treatments (9-11) based on the expression profiles of those genes. In this report, we carried out unsupervised analyses of microarray expression profiling data to identify gene lists that segregate advanced CRC patients based on response to 5-FU/CPT-11 therapy. In parallel, we profiled and carried out unsupervised analyses of paired drug sensitive and resistant CRC cell lines to further identify genes associated with drug resistance. Furthermore we have functionally tested whether any of the genes contained within these lists are functionally involved in chemotherapeutic resistance/sensitivity in colorectal cancer cell lines. For expression profiling in this study, we have used a Colorectal Cancer disease specific array (DSA), which contains 61,528 probesets and encodes 52,306 transcripts confirmed as being expressed in CRC and normal colorectal tissue. This array contains transcripts that
have not been available for previous expression analysis studies (12). The generation and utility of other DSAs using a similar technical approach have been previously reported (13-15). The power of the current study is that we have used a systems biology approach of transcriptional profiling with functional testing of the identified genes to highlight potential novel drug targets and/or biomarkers, which could be used to potentially improve response rates for advanced CRC.
Materials and Methods

Patient Samples. These have been previously described (16). Briefly, twenty patients with metastatic colorectal cancer were included in the present study. All patients provided written fully informed consent as per IRB guidelines in the University of Southern California and approval was granted from this body. These patients underwent biopsy of colorectal liver metastases prior to commencing irinotecan/5-FU chemotherapy on the IFL schedule: CPT-11 125mg/m² i.v. over 90 minutes, Leucovorin (LV) 20mg/m² as i.v. bolus injection immediately prior to 5-FU and 5-FU 500mg/m² as i.v. bolus injection administered weekly for four weeks and repeated every six weeks.

CT imaging for response evaluation using WHO criteria was performed every 6 weeks. Of these 20 patients, 1 had a complete response to treatment, 10 had a partial response to treatment and 9 had progressive disease on treatment. For the purpose of this study we have further defined ‘responders’ as those patients with either complete or partial response and ‘non-responders’ as those patients with progressive disease. We have specifically excluded patients with stable disease on chemotherapy from the study.

Materials. 5-FU and SN38 were purchased from Sigma Chemical Co. (St. Louis, MO) and Abatra Technology Co, LTD (China) respectively.

Cell culture. All CRC cells were grown as previously described (17). Following receipt, cells were grown up, and as soon as surplus cells became available, they were frozen as a seed stock. All cells were passaged for a maximum of 2 months, after which new seed
stocks were thawed for experimental use. All cell lines were tested for mycoplasma contamination at least every month. LS174T (2008), SW620 (2008) and RKO (2001) cells were obtained from the American Type Culture Collection [ATCC; authentication by short tandem repeat (STR) profiling/karyotyping/isoenzyme analysis] and maintained in Dulbecco's modified Eagle's medium (DMEM). The HCT116 human colon cancer cell line was kindly provided by Prof. Bert Vogelstein (Johns Hopkins University, Baltimore, MD) in 2003 and was grown in McCoy’s 5A medium. LoVo cells were provided for AstraZeneca in 2003. HCT116, HT29, LoVo and RKO cell lines were validated by STR profiling by LGC Standards (18) in May 2011. The 5-FU- and oxaliplatin-resistant HCT116 sub-lines and were generated in our laboratory as previously described (19). The FLIP overexpressing HCT116 cell lines were previously described (20). All medium was supplemented with 10% dialysed FCS, 50µg/mL penicillin-streptomycin, 2mM L-glutamine, and 1mM sodium pyruvate (all medium and supplements from Invitrogen Life Technologies Corp., Paisley, United Kingdom). All cell lines were maintained at 37°C in a humidified atmosphere containing 5% CO₂.

**Microarray analysis.** Total RNA was extracted from 20 pre-treatment metastatic tumour biopsies from patients with advanced colorectal cancer and also profiled on the Colorectal cancer DSA (Almac Diagnostics, Craigavon, UK). In addition, *in vitro* analyses were also carried out using the Colorectal cancer DSA. Briefly, HCT116 parental cells were either untreated (0h control) or treated with either 5µM 5-FU or 5nM SN38 for 24 hours as outlined in Fig. 2A (acutely altered genes). Also, untreated 5-FU-resistant and SN38-resistant cells were analyzed to identify those genes that are basally
deregulated between parental and resistant cells. Total RNA was isolated from three independent experiments using the RNA STAT-60™ Total RNA isolation reagent (Tel-Test, Inc., Texas, USA) according to the manufacturer’s instructions. For both the clinical and in vitro studies, RNA was sent to Almac Diagnostics (Craigavon, UK) for cDNA synthesis, cRNA synthesis, fragmentation and hybridisation onto the Colorectal cancer DSA. Detailed experimental protocols and raw expression data are available within the ArrayExpress repository (21) (Accession number E-MEXP-1692 (Clinical analysis) and E-MEXP-1691 (in vitro analysis)).

Unsupervised Classification Analysis. Unsupervised classification analysis was carried out using Principal Components Analysis (PCA). All PCA was carried out using the Partek® software (version 6.3, Partek Inc., St. Louis, MO, USA). Briefly, each microarray experiment (5-FU basal, 5-FU inducible, SN38 basal, SN38 inducible and 5-FU/irinotecan clinical) was initially normalised and then underwent minimal flag filtering prior to PCA analysis. Following PCA analysis of each experiment, the results were examined to determine which principal component (PC) lead to the greatest separation between the two treatment groups. The PC that lead to the maximal treatment group separation was then isolated and the top ten positive and top ten negative component loadings were listed for each experiment.

Quantitative reverse transcription-PCR analysis. Total RNA was isolated as described above. Reverse transcription was carried out using 2µg of RNA using a Moloney murine leukemia virus–based reverse transcriptase kit (Invitrogen) according to the manufacturer’s
instructions. Quantitative reverse transcription-PCR (RT-PCR) amplification was carried out in a final volume of 10µL containing 5µL of 2xSYBR green master mix (Qiagen), 4µL of primers (2µM), and 1µl of cDNA using an Opticon DNA Engine Thermal Cycler (Bio-Rad Laboratories, Inc., Waltham, MA) using methods previously described (16). All amplifications were primed by pairs of chemically synthesized 18- to 22-mer oligonucleotides designed using the Primer3 primer design software (22).

Statistical Analysis. All t tests and 2-way ANOVAs were calculated using the GraphPad software (Prism4). Specifically, t tests were unpaired, 2-tailed using 95% confidence intervals. 2-way ANOVA was calculated using 95% confidence intervals and a Bonferroni post-hoc test.

siRNA Plate Analysis. All siRNAs were supplied by Qiagen (Crawley, UK). siRNA screening was performed using siRNAs targeting pre-selected genes identified from microarray analysis. All Stars Negative control and All Stars Death control were used as non-targeting (scrambled) and positive controls, respectively. Transfection conditions were optimized using siRNAs with known effect on cell survival (FLIP and XIAP) (23-25). HCT116 cells were reverse-transfected using HiPerFect transfection reagent (Qiagen, Crawley, UK) to a final concentration of 5nM siRNA. After 24h, drug/solvent control was added: 5FU and SN38 (~IC_{30} doses). 48 hours later, MTT (cell viability) and ToxiLight (cell death) (Promega UK Ltd) assays were performed. The measurement from each well was normalised to the scrambled control. ToxiLight values were divided by MTT values to give a measurement of ‘Relative toxicity’ for each silenced gene. Significance and
interaction effects were measured using t-tests, one-way ANOVA and two-way ANOVA to assess statistical significance of changes compared to control siRNA.

**Cell viability analysis.** Cell viability was determined using MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). For the siRNA plate analysis the analysis was carried out at 72h post transfection. For the combination index (CI) synergy calculation the analysis was carried out at 24h or 48h post transfection and drug treatment. CI values <1, 1, and >1 indicating synergism, additivity, and antagonism, respectively. For synergistic interactions, CI values between 0.8-0.9 indicate slight synergy, 0.6-0.8 indicate moderate synergy, 0.4-0.6 indicate synergy and those <0.4 indicate strong synergy (26).

**Western Blot analysis.** Western blot analysis was carried out as previously described SART1 (Abcam, Cambridge, UK), FLIP (NF6; Alexis, San Diego, CA), Caspase 8 (12F5; Alexis) and Poly-ADP-Ribose-Polymerase-1 (PARP; eBioscience, San Diego, CA) mouse monoclonal antibodies were used in conjunction with a horseradish peroxidase-conjugated sheep anti-mouse secondary antibody (Amersham, Buckinghamshire, UK). Equal loading was assessed using GAPDH (AbD Serotec, Kidlington, UK).

**Flow cytometric analysis.** Annexin V/PI analysis was carried out using the EPICS XL Flow Cytometer (Coulter, Miami, FL, USA). Cells were harvested and analyzed according
to manufacturer’s instructions (BD Biosciences). Annexin V/PI staining was carried out at 72h post transfection.
Results

Transcriptional profiling of metastatic CRC biopsies and drug resistant cell lines

Using the Colorectal DSA, we performed microarray expression profiling of pre-treatment metastatic CRC patient biopsies (n=20). After appropriate background corrections and normalisations using the Robust Multichip Average (RMA) method (27), expression values from all the 61,528 probes were used for further analysis. In addition, we also carried out an in vitro transcriptional profiling experiment using the same platform. We used a HCT116 colorectal cancer cell line panel made up of parental drug sensitive cells and daughter cell lines with acquired resistance to 5-FU or SN38 (the active metabolite of irinotecan) (19). The transcriptional profiles of the HCT116 parental cells following treatment with either 5μM 5-FU or 5nM SN38 for 24h were examined. In addition, we also compared the basal transcriptional profiles of the HCT116 5-FU-resistant and SN38-resistant daughter cell lines with the parental cell line. All in vitro microarray analyses were validated by quantitative RT-PCR and the results demonstrated a strong overall concordance with the original microarray study (16) (Supplementary Table 1). In order to identify potential targets that may regulate drug sensitivity, we used the unsupervised classification approach of Principal Components Analysis (PCA).

Unsupervised classification

For the unsupervised analysis, five ‘experiments’ were created: clinical (responders v non-responders), 5-FU basal (sensitive v resistant), 5-FU inducible (parental untreated v parental 5-FU treated), SN38 basal (sensitive v resistant) and SN38 inducible (parental untreated v parental treated). Principal Components Analysis (PCA) was used as the
unsupervised method, and all data from each of the five experiments was initially flag filtered. For the clinical analysis it was the 3rd Principal Component (PC) (9.8% variability) that gave the best separation based on patient response, although within this there were still a number of mis-classifications (Figure 1A). The top 10 probesets that correlated positively or negatively with PC3 were selected (Supplementary Table 2). For the 5-FU in vitro experiments (basal and inducible), PCA of the flag-filtered data showed a clear separation of sample groups. In both cases, this distinction was evident from the first principal component (Figures 1B and 1C). The top 10 probesets from the extreme positive or negative values of the component loadings that correlated maximally with PC1 were selected (Supplementary Tables 3 and 4). For the SN38 in vitro experiments, the PC that accounted for the maximum variability in the dataset, PC1 (35.8%), was able to differentiate between the basal expression changes observed between parental and SN38-resistant daughter cells, although one of the parental cells was misaligned (Figure 1D). However, in the case of SN38 treatment in the parental cells, separation based on drug treatment was only evident from the second principal component (PC2: 25.6%) of the dataset, with one replicate from each class misaligned (Figure 1E). In each case the top 10 probesets from the extreme positive or negative values of the component loadings that correlated maximally with PC1 (SN38 basal) or PC2 (SN38 inducible) were selected (Supplementary Table 5 and 6). For each of the above described experiments, 5 probesets from the top ten positive and negative component loadings were selected for further functional analysis (Table 1); those that were omitted were either transcribed sequences or in antisense orientation.
Functional assessment of unsupervised genes

The clinical and *in vitro* genes identified from the unsupervised analyses (Table 1) were investigated further by RNAi for their functional relevance in mediating sensitivity to either 5-FU or SN38. For the initial screening process, custom-designed siRNA plates included all genes for which siRNA sequences were available (n=50). In each case, the effect of target gene silencing was examined alone and also in combination with either 5µM 5-FU (IC30(48h)) or 5nM SN38 (IC30(48h)) in HCT116 CRC cells. For each experiment, two assays were carried out, cell viability (MTT assay) and cell death (Toxilight assay). From this the relative toxicity was calculated as the ratio of cell death to cell viability. Cells were transfected with siRNA for 24h prior to 48h treatment with chemotherapy.

Of the genes identified from the clinical PCA analysis, *TNFS14, MAPK9, RAPGEF2* and *RPS9* silencing resulted in increased relative toxicity when combined with either 5-FU or SN38 compared to either treatment alone (Figure 2A). Silencing of TNFS14 or RPS9 resulted in enhanced toxicity with 5-FU only, while silencing of MAPK9 enhanced the effect of SN38, but not 5-FU. Silencing of the genes identified from the *in vitro* PCA which were associated with 5-FU response identified a number of chemo-sensitizing genes: *GART, BTN3A2, ASSDHPPT, RAD51AP1, PTRF, PRKCDDBP, TSFM, MGA* and *PSMA2* (Figure 2B). The silencing of either RAD51AP1 or PTRF significantly enhanced the relative toxicity of both 5-FU and SN38 treatment, whereas, silencing the remainder of these 5-FU response-associated genes only significantly increased sensitivity to 5-FU treatment. Analysis of the genes identified from the SN38 *in vitro* PCAs identified 8
positive hits: *AGPAT6, SLC30A7, E2F3, LNPEP, CREF1, RPL28, RFC4* and *SART1* (Figure 2C). In all cases, gene silencing resulted in supra-additive interactions with both 5-FU and SN38. Validation of gene silencing was confirmed by quantitative RT-PCR, with silencing of target genes ranging from 45%-96% knock-down compared to non-targeting control siRNA (Supplementary Figure 1).

*Validation of positive hits in colorectal cancer cell line panel*

One gene was selected from each of the analysis for testing across a CRC cell line panel. These three genes were selected based on displaying a synergistic interaction with both 5-FU and SN38 when silenced. Therefore, RAPGEF2 was selected from the clinical analysis, PTRF from the 5-FU *in vitro* analysis and SART1 from the SN38 *in vitro* analysis. A range of CRC cell lines with varying mutational backgrounds were tested: LoVo, RKO, HT29, SW620 and LS174T. Cell death and cell viability assays were carried out as before, and the relative toxicity measured. In this screen, two siRNA sequences were included. The results showed that silencing either RAPGEF2 or PTRF did not sensitize any cell line, other than HCT116, to either 5-FU or SN38 treatment, therefore the effect of these genes appear to be cell line-dependent (data not shown). However, in the extended cell line panel, silencing of SART1 with either siRNA produced similar results with either additive or synergistic increases in relative toxicity when combined with either chemotherapy treatment (Figure 3A-E).
**SART1 silencing induces apoptosis in colorectal cancer cells**

SART1 protein expression was up-regulated in response to chemotherapy treatment (Figure 4A). Importantly, analysis of PARP cleavage (a hallmark of apoptosis) indicated that SART1 silencing induced enhanced chemotherapy-induced apoptosis after 48h treatment (Figure 4A). To examine the levels of cell death induced following SART1 silencing alone and in combination with chemotherapy, Annexin V/PI staining was carried out in several CRC cell lines. In the HCT116 cell line, SART1 silencing alone resulted in ~43% cell death, and apoptosis was further increased when SART1 silenced cells were co-treated with 5-FU or SN38 (Figure 4B). Similar results were demonstrated with a second siRNA sequence for SART1 (data not shown). Moreover, similar results were obtained in other CRC cell line models, with SART1 silencing inducing apoptosis in LS174T and RKO cell lines (Figures 4C and D).

**Silencing of SART1 results in synergistic interactions with either 5-FU or SN38**

To determine whether silencing of SART1 results in synergistic interactions with chemotherapy, cell viability assays were carried out, and Combination Index (CI) values calculated. Synergistic interactions were observed between chemotherapy and SART1 silencing in the HCT116 (Figures 5A and B), the LS174T (Figures 5C and D) and the RKO (Figures 5E and F) cell lines.

**The cell death induced by SART1 silencing is caspase 8- and FLIP-dependent**

Previous experiments had demonstrated that SART1 silencing resulted in apoptotic cell death, therefore we investigated whether the mechanism was caspase-dependent, using
the pan-caspase inhibitor ZVAD. The cell death observed following SART1 silencing was apoptotic (Annexin V positive) and was completely abrogated following cotreatment with ZVAD (Figure 6A). Analysis of caspase activity following SART1 silencing indicated that caspase 8 was highly activated (Figure 6B). To assess whether SART1 siRNA-induced apoptosis was caspase 8-dependent, caspase 8-specific siRNA was co-transfected with SART1 siRNA. Apoptotic cell death induced following SART1 silencing was completely abrogated following caspase 8 co-silencing at both 24 and 48h (Figure 6B). Caspase 8 activity assays demonstrated that caspase 8 activity was inhibited following caspase 8 silencing (Figure 6C). In addition, the increased caspase 3/7 activity that was observed following SART1 silencing at 24 and 48h was also completely abrogated following caspase 8 co-silencing (Figure 6C). Furthermore, Western blotting demonstrated that PARP cleavage following SART1 silencing was prevented by caspase 8 co-silencing (Figure 6D). The decreased expression of pro-caspase 8 in the SART1 silenced cells (Figure 6D, lane 3) is indicative of pro-caspase 8 activation. Notably, the expression of the endogenous caspase 8 inhibitor c-FLIP<sub>L</sub> was observed to be down-regulated following SART1 silencing. Importantly, c-FLIP<sub>L</sub> down-regulation following SART1 silencing was not a downstream effect of apoptosis induction as it was also observed in samples in which caspase 8 was co-silenced. Moreover, SART1 siRNA-induced apoptosis was attenuated in HCT116 cells stably overexpressing FLIP<sub>L</sub> (Figure 6E). These results suggest that down-regulation of c-FLIP<sub>L</sub> following SART1 silencing is an upstream effect that leads to caspase 8-dependent apoptosis and enhanced drug-induced apoptosis.
Discussion

In the current study we utilised a systems biology approach incorporating transcriptional profiling, bioinformatics and functional analyses to identify key mediators of 5-FU and SN38 sensitivity in colorectal cancer that may represent novel drug targets and/or biomarkers. Following minimal filtering, unsupervised analysis was carried out on both the clinical and in vitro genelists using PCA. The reason for using both clinical and in vitro data was to try and identify potentially clinically relevant targets that could also be validated within an in vitro system. In addition, PCA was chosen as the classification approach as it represents a completely unbiased approach. Furthermore, due to the fact that the clinical sample size used was small, a supervised method approach may have significantly over estimated the predictive ability of the identified genes. Using the unsupervised approach, PCA identified a total of 100 genes, 50 of which were taken forward for functional testing using a custom-designed siRNA screen. The siRNA screen incorporated multiple siRNA sequences across a panel of several CRC cell lines and identified squamous cell carcinoma antigen recognized by T cells or SART1 as a potential mediator of 5-FU and SN38 sensitivity in this disease setting.

We functionally tested 50 of the 100 transcripts by siRNA screening and found that a significant number of these did play a role in mediating chemotherapy response in the initial cell line model system. Many of the 50 untested transcripts represented hypothetical proteins, and some were antisense RNAs, which made testing their functional significance more difficult. However, while most of the remaining untested transcripts have not been previously implicated in either colorectal cancer progression or chemotherapy response,
some potentially may have a role. Such genes include CSNK2A2 (5-FU in vitro-related) and CCNDBP1, TNFAIP8 and GDI2 (clinically-related). CCNDBP1 negatively regulates cell cycle progression through the inhibition of the cyclinD1/CDK4 complex (28, 29). CCNDBP1 is located on chromosome 15q15, which is associated with loss of heterozygosity (LOH) in many tumour types including colon (28, 29). It is down-regulated in tumours compared to matched normal and therefore has been associated with tumour suppression (28). TNFAIP8 has been shown to regulate apoptosis in thymocytes (30). Interestingly, TNFAIP8 can block caspase-mediated apoptosis, contains a death effector domain (DED) and has been hypothesized to be a novel member of the FLIP family (31). GDI2 has been identified in a number of proteomic studies as a potential biomarker for pancreatic and ovarian cancer (32, 33). Indeed, GDI2 has been identified as a marker for chemo-resistance in ovarian cancer (32). CSNK2A2 is known to be over-expressed in cancers, including CRC. It has been associated with disease progression in CRC via a proteomic approach (34). Of interest, CSNK2A2 protects colon cancer cells from TRAIL-induced apoptosis (35). The pro-survival and inhibition of apoptosis that is associated with CSNK2A2 is mediated through its ability to induce survivin expression via the Wnt pathway (36). Although these targets were not assessed for functional significance, they may still represent potential biomarkers or therapeutic targets for inhibiting drug resistance in this disease setting.

SART1 is a bicistronic gene that encodes two proteins, one of which is 800 amino acids long and contains a leucine zipper and the other that is 259 amino acids long that does not contain the leucine zipper. The SART1(800) protein is located in the nucleus of the
majority of proliferating cells, while the SART1(259) protein is located in the cytosol of epithelial cancers. In this study, we focussed on SART1(800), the main function of which is thought to be in the recruitment of the tri-snRNP to the pre-spliceosome (37). Therefore, SART1 may be critical for pre-mRNA splicing. SART1(800) protein is expressed in 100% of CRC cell lines, 55% of CRC tissue and 0% of non-tumour tissue (38). Hypoxia inducible factor or HAF is the murine homolog of SART1, and several studies have demonstrated that HAF binds to and regulates the activity of the EPO receptor, VEGF and HIF-1α (39, 40). HAF binds and regulates HIF-1α activity independent of oxygen levels (40). SART1 has also been identified as a novel SUMO1 and SUMO2 target protein (41-43).

SART1 has been associated with the development and progression of head and neck squamous cell carcinoma. Again, in this disease setting, there was a much higher tumour expression compared to normal (44). Kittler et al. carried out an siRNA screen to identify genes that were essential for cell division in breast cancer. They identified SART1 as a gene essential for cell division in breast cancer, with SART1 depletion displaying similar defects to either CENPE or KIF11 depletion. These defects following SART1 depletion may indicate that SART1 plays a direct role in cell division or may have an indirect effect caused by defective pre-mRNA splicing (45). Following this study, a second study was carried out by Olson et al., which examined whether the genes identified from the former study were associated with breast cancer risk. The results demonstrated that four single nucleotide polymorphisms (SNPs) were present in SART1, and two were associated with increased risk of breast cancer, while the other two were associated with a decreased risk.
of breast cancer development (46). The authors concluded that genetic variation in *SART1* may be associated with breast cancer development.

The current study has demonstrated that SART1 silencing sensitises CRC cells to 5-FU or SN38 treatment via apoptosis induction. The mechanism of cell death is caspase-dependent, specifically caspase 8-dependent. In addition, the results demonstrate that SART1 silencing leads to c-FLIP\textsubscript{L} down-regulation. Our previous studies have demonstrated that c-FLIP\textsubscript{L} is a key regulator of chemotherapy-induced cell death in CRC and other tumour types (20, 23-25, 47). The down-regulation of c-FLIP\textsubscript{L} was not a consequence of cell death as we also carried out experiments in which caspase 8 and SART1 were co-silenced and demonstrated that the cells did not undergo apoptosis, however, c-FLIP\textsubscript{L} was still down-regulated. Moreover, apoptosis induced by SART1 silencing was attenuated in c-FLIP\textsubscript{L} overexpressing cells. These results suggest that SART1 expression is important for continued c-FLIP\textsubscript{L} expression. c-FLIP regulation is highly complex and involves transcriptional and post-transcriptional regulation by a number of key signal transduction pathways, such as NF\textsubscript{B}, JNK, *c-myc*, *c-fos* and PKC (48). Preliminary data suggest that the effects of SART1 on c-FLIP expression are post-transcriptional (data not shown): the mechanistic basis of SART1’s regulation of c-FLIP is the subject of ongoing studies. The current study has demonstrated that silencing of SART1 enhanced chemotherapy-induced cell death via c-FLIP down-regulation. Thus, c-FLIP and/or SART1 may represent predictive biomarkers of response to chemotherapy in CRC.
In conclusion, the current study has used a systems biology approach to identify a number of novel regulators of chemo-resistance in colorectal cancer, most notably SART1, which regulates expression of the critical apoptosis-regulating and drug resistance-associated protein c-FLIP. Future studies will assess the clinical relevance of SART1 expression as a prognostic and predictive biomarker in colorectal cancer.
Acknowledgements

We would like to thank Ms Cathy Fenning for technical support.
References


21. http://www.ebi.ac.uk/arrayexpress/


Table 1: The top 50 genes identified from PCA of the clinical, 5-FU in vitro basal, 5-FU in vitro inducible, SN38 in vitro basal and SN38 in vitro inducible transcriptional profiling experiments. Listed is the probe ID, gene symbol and gene name.

<table>
<thead>
<tr>
<th>ProbeID</th>
<th>Gene Symbol</th>
<th>Gene Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADXCRIH.1569.C1_s_at</td>
<td>RPS27L</td>
<td>Homo sapiens ribosomal protein S27-like (RPS27L) mRNA.</td>
</tr>
<tr>
<td>ADXRAD_B1820604_s_at</td>
<td>MAPK9</td>
<td>Homo sapiens mitogen-activated protein kinase 9 (MAPK9) transcript</td>
</tr>
<tr>
<td>ADXCRAF_536890_C1_s_at</td>
<td>PDE4D</td>
<td>Homo sapiens cAMP-specific phosphodiesterase (PDE4D) mRNA untranslatable region p</td>
</tr>
<tr>
<td>ADXCRIH.4.C1_at</td>
<td>RPS9</td>
<td>Homo sapiens ribosomal protein S9 (RPS9) mRNA.</td>
</tr>
<tr>
<td>ADXCRAF_BX640769_x_at</td>
<td>RAPGEF2</td>
<td>Rap guanine nucleotide exchange factor (GEF) 2</td>
</tr>
<tr>
<td>ADXCRAF_AL133646_s_at</td>
<td>GMEB2</td>
<td>Homo sapiens glucocorticoid modulatory element binding protein 2</td>
</tr>
<tr>
<td>ADXCRAF_AL832400_x_at</td>
<td>NLRP1</td>
<td>NLR family pyrin domain containing 1</td>
</tr>
<tr>
<td>ADXCRAF_NM_152345_s_at</td>
<td>ANKRD13B</td>
<td>Homo sapiens ankyrin repeat domain 13B (ANKRD13B) mRNA</td>
</tr>
<tr>
<td>ADXCRAF_CV571495_x_at</td>
<td>TNFSF14</td>
<td>Homo sapiens tumor necrosis factor (ligand) superfamily member 14</td>
</tr>
<tr>
<td>ADXRAD.6977.C1_at</td>
<td>GART</td>
<td>Homo sapiens phosphoribosylglycinamidase formerly transferase</td>
</tr>
<tr>
<td>ADXCRIH.2762_C1_s_at</td>
<td>MRPL21</td>
<td>Homo sapiens mitochondrial ribosomal protein L21 (MRPL21) nuclear</td>
</tr>
<tr>
<td>ADXCRAF_CN279751_s_at</td>
<td>IRAK1</td>
<td>Homo sapiens interleukin-1 receptor-associated kinase 1 (IRAK1)</td>
</tr>
<tr>
<td>ADXRAD_GC016330_s_at</td>
<td>RAD51P1</td>
<td>Homo sapiens RAD51 associated protein 1 (RAD51P1) mRNA</td>
</tr>
<tr>
<td>ADXRAD_BX415970_x_at</td>
<td>AASDHPP</td>
<td>Aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase</td>
</tr>
<tr>
<td>ADXRAD_AL135445_at</td>
<td>BTN3A2</td>
<td>Homo sapiens butyrophilin subfamily 3 member A2 (BTN3A2) mRNA</td>
</tr>
<tr>
<td>ADXRAD.4320.C1_s_at</td>
<td>OMA1</td>
<td>Homo sapiens OMA1 homolog zinc metalloprotease (S. cerevisiae)</td>
</tr>
<tr>
<td>ADXRAD_AL545542_x_at</td>
<td>PTRF</td>
<td>Homo sapiens polymerase I and transcript release factor (PTRF)</td>
</tr>
<tr>
<td>ADXRAD_TM.32242x_at</td>
<td>PLXNA1</td>
<td>Homo sapiens plexin A1 (PLXNA1) mRNA</td>
</tr>
<tr>
<td>ADXRAD.7079.C1_s_at</td>
<td>PRKCDBP</td>
<td>Homo sapiens protein kinase C delta binding protein (PRKCDBP)</td>
</tr>
<tr>
<td>ADXRAD.BX100631_s_at</td>
<td>SLC12A8</td>
<td>Homo sapiens solute carrier family 12 (potassium/chloride)</td>
</tr>
<tr>
<td>ADXRAD.888.C1_s_at</td>
<td>TRLF</td>
<td>Homo sapiens ash2 (absent small or homeotic)-like (Drosophila)</td>
</tr>
<tr>
<td>ADXRAD.AF155810_s_at</td>
<td>SLC25A14</td>
<td>Homo sapiens solute carrier family 25 (mitochondrial carrier)</td>
</tr>
<tr>
<td>ADXRAD.1085.C1_at</td>
<td>TFR</td>
<td>Homo sapiens T cell translation elongation factor mitochondrial</td>
</tr>
<tr>
<td>ADXRAD_C3317.C1_s_at</td>
<td>PSMA2</td>
<td>Homo sapiens proteasome (prosome macropain) subunit alpha type 2</td>
</tr>
<tr>
<td>ADXRAD.6687.C1_at</td>
<td>CDK3</td>
<td>Homo sapiens cyclin-dependent kinase 3 (CDK3) gene complete cds</td>
</tr>
<tr>
<td>ADXRAD.XM_301698_s_at</td>
<td>MGA</td>
<td>Homo sapiens MAX gene associated (MGA) mRNA</td>
</tr>
<tr>
<td>ADXRAD.H10316_s_at</td>
<td>BAT4</td>
<td>Homo sapiens HLA-B associated transcript 4 (BAT4) mRNA</td>
</tr>
<tr>
<td>ADXRAD.5351.C1_s_at</td>
<td>FAM102A</td>
<td>Homo sapiens family with sequence similarity 102 member A</td>
</tr>
<tr>
<td>ADXRAD.3223_C1_s_at</td>
<td>TMC4</td>
<td>Homo sapiens transmembrane channel-like 4 (TMC4) mRNA</td>
</tr>
<tr>
<td>ADXRAD.124866_at</td>
<td>AGPAT6</td>
<td>1-acylglycerol-3-phosphate O-acyltransferase 6 (lysophosphatic acid acyltransferase)</td>
</tr>
<tr>
<td>ADXRAD.CB161421_s_at</td>
<td>PIK3AP1</td>
<td>Homo sapiens phosphoinositide-3-kinase adaptor protein 1 (PIK3AP1)</td>
</tr>
<tr>
<td>ADXRAD.5659_s_at</td>
<td>PAPSS1</td>
<td>Homo sapiens 3-phosphohydrolase 5-phosphosulfate synthase 1</td>
</tr>
<tr>
<td>ADXRAD.9008.C2_s_at</td>
<td>CCG21A</td>
<td>Homo sapiens coiled-coil and C2 domain containing 1A (CCG21A)</td>
</tr>
<tr>
<td>ADXRAD.3630_s_at</td>
<td>BTN3A2</td>
<td>Homo sapiens butyrophilin subfamily 3 member A2 (BTN3A2) mRNA</td>
</tr>
<tr>
<td>ADXRAD.BX640630_s_at</td>
<td>SLC30A7</td>
<td>Homo sapiens solute carrier family 30 (zinc transporter) member 7</td>
</tr>
<tr>
<td>ADXRAD.CA776658_s_at</td>
<td>WDR48</td>
<td>Homo sapiens WD repeat domain 48 (WDR48) mRNA</td>
</tr>
<tr>
<td>ADXRAD_AL34333_s_at</td>
<td>SUH3W</td>
<td>Homo sapiens suppressor of hairy wing homolog 3 (Drosophila)</td>
</tr>
<tr>
<td>ADXRAD.BC016847_s_at</td>
<td>E2F3</td>
<td>Homo sapiens E2F transcription factor 3 (E2F3) mRNA</td>
</tr>
<tr>
<td>ADXRAD_AA311408_x_at</td>
<td>LNPEP</td>
<td>Homo sapiens mRNA for leucyl/cystinyl aminopeptidase variant protein</td>
</tr>
<tr>
<td>ADXRAD.8916.C1_s_at</td>
<td>CGREF1</td>
<td>Homo sapiens cell growth regulator with EF-hand domain 1 (CGREF1)</td>
</tr>
<tr>
<td>ADXRAD_BE870333_at</td>
<td>RPL28</td>
<td>Homo sapiens ribosomal protein L28 (RPL28) mRNA</td>
</tr>
<tr>
<td>ADXRAD.8036.C1_at</td>
<td>ZNF669</td>
<td>Homo sapiens zinc finger protein 669 (ZNF669) mRNA</td>
</tr>
<tr>
<td>ADXRADSS.Hs#S648776_s_at</td>
<td>RPL32</td>
<td>Homo sapiens ribosomal protein L32 (RPL32) transcript variant 2</td>
</tr>
<tr>
<td>ADXRAD.BQ216862_s_at</td>
<td>WDR68</td>
<td>Homo sapiens WD repeat domain 68 (WDR68) mRNA</td>
</tr>
<tr>
<td>ADXRAD_BM54228_s_at</td>
<td>RFC4</td>
<td>Homo sapiens replication factor C (activator 1) 4 37kDa (RFC4)</td>
</tr>
<tr>
<td>ADXRAD_CN368539_s_at</td>
<td>DOLPP1</td>
<td>Homo sapiens dolichyl pyrophosphate phosphatase 1 (DOLPP1) mRNA</td>
</tr>
<tr>
<td>ADXRAD_BM793751_s_at</td>
<td>BMS1</td>
<td>Homo sapiens BMS1 homolog ribosome assembly protein (yeast)</td>
</tr>
<tr>
<td>ADXRAD_CN297094_s_at</td>
<td>MAST2</td>
<td>Homo sapiens microtubule associated serine/threonine kinase 2</td>
</tr>
<tr>
<td>ADXRAD.5126.C1_s_at</td>
<td>SART1</td>
<td>Homo sapiens squamous cell carcinoma antigen recognized by T cells</td>
</tr>
</tbody>
</table>
Figure Legends

Figure 1. Results from unsupervised classification analysis using principal component analysis (PCA) for (A) clinical data displaying PC1 against PC3, (B) in vitro 5-FU basal data displaying PC1 against PC2, (C) in vitro 5-FU inducible data displaying PC1 against PC2, (D) in vitro SN38 basal data displaying PC1 against PC2 and (E) in vitro SN38 inducible data displaying PC1 against PC2. A solid black line denotes the point of separation in the respective PC. Each sample group is displayed in either red or blue.

Figure 2: Results from the initial siRNA screen in the HCT116 cells. The graphs show the relative toxicity, as assessed from MTT and toxilight assays, for all positive genes from the: (A) clinical analysis, (B) the 5-FU in vitro analysis, and (C) the SN38 in vitro analysis. Displayed are those genes that show an interaction between gene silencing and either 5-FU or SN38 treatment as measured by 2-way ANOVA. Synergistic interactions are highlighted as *=p<0.05, **=p<0.01 and ***=p<0.001.

Figure 3: Results from the cell line panel siRNA screen. The graphs show the relative toxicity, as assessed from MTT and toxilight assays, for SART1, PTRF and RAPGEF2 for the (A) LoVo, (B) RKO (C) LS174T, (D) HT29, (E) SW620 cell lines. Displayed is the effect of gene silencing alone and in combination with either 5-FU or SN38 treatment. Statistical significance between gene silencing alone (siRNA) and gene silencing in combination with chemotherapy are assessed by an unpaired 2 way t test.
statistical significance are highlighted as *\( p<0.05 \), **\( p<0.01 \) and ***\( p<0.001 \). Two siRNA sequences were included for each gene, indicated by (1) and (2).

**Figure 4:** (A) Western blot analysis of SART1 expression and PARP cleavage in HCT116 cells transfected with control (-) or SART1 (+) siRNAs and co-treated with 5-FU (IC\(_{30}(48\text{h})\)) or SN38 (IC\(_{30}(48\text{h})\)) for 24 and 48 h. (B, C and D) Flow cytometric analyses of apoptosis following SART1 silencing alone or in combination with either 5-FU (IC\(_{30}(48\text{h})\)) or SN38 (IC\(_{30}(48\text{h})\)) in HCT116 (B), RKO (C) and LS147T (D). All cells were reversed transfected with SART1 siRNA for 24h prior to a 48h treatment with chemotherapy.

**Figure 5:** Cell viability assays were conducted in (A and B) HCT116 (C and D) LS174T, and (E and F) RKO cell lines in response to SART1 siRNA (0.5, 1 and 5nM) and either SN38 (1, 5 and 10nM) or 5-FU (1, 5 and 10\( \mu \text{M} \)) for 72 h. To evaluate the interaction between chemotherapy and SART1 silencing, we used the method of Chou and Talalay (26). CI values <1, =1, and >1 indicating synergism, additivity, and antagonism, respectively. For synergistic interactions, CI values between 0.8-0.9 indicate slight synergy, 0.6-0.8 indicate moderate synergy, 0.4-0.6 indicate synergy and those <0.4 indicate strong synergy.

**Figure 6:** (A). Flow cytometric analysis of apoptosis in HCT116 cells following treatment with control (SC) or SART1 siRNA (1nM) alone or in combination with chemotherapy (IC\(_{30}(48\text{h})\)) for 72h in the presence and absence of the pan-caspase
inhibitor, ZVAD (10μM). (B). Flow cytometric analysis of apoptosis in HCT116 cells following transfection with SC or SART1 siRNA (5nM) alone or in combination caspase 8 siRNA (10nM). (C) Caspase-Glo® assay measuring caspase 8 activity or caspase 3/7 activity in HCT116 cells following transfection with SC or SART1 siRNA (5nM) alone or in combination caspase 8 siRNA (10nM). (D). Western blot analysis of SART1, pro-caspase 8 and FLIP<sub>L</sub> expression following transfection with SC or SART1 siRNA (5nM) alone or in combination caspase 8 siRNA (10nM). All experiments are representative of three independent experiments. (E). Flow cytometric analysis of apoptosis in parental and c-FLIP<sub>L</sub> overexpressing cells (FL17 and FL24) following transfection with SC or SART1 siRNA (5nM) for 24 hours. Statistical significance was assessed by using an unpaired two-tailed t test with *** = p<0.001, ** = p<0.01 and * = P<0.05.
Figure 1

**A Clinical samples**

**B 5FU Basal**

**C 5FU Inducible**

**D SN38 Basal**

**E SN38 Inducible**
Figure 2

A. Clinical Unsupervised Analysis

B. 5-FU in vitro Unsupervised Analysis

C. SN38 in vitro Unsupervised Analysis
Figure 3

A) **LoVo**

- Con
- 5-FU
- SN38

B) **RKO**

- Con
- 5-FU
- SN38

C) **LS174T**

- Con
- 5-FU
- SN38

D) **HT29**

- Con
- 5-FU
- SN38

E) **SW620**

- Con
- 5-FU
- SN38
Figure 4

A

<table>
<thead>
<tr>
<th></th>
<th>24h</th>
<th></th>
<th>48h</th>
</tr>
</thead>
<tbody>
<tr>
<td>Con</td>
<td>-</td>
<td>Con</td>
<td>-</td>
</tr>
<tr>
<td>5-FU</td>
<td>+</td>
<td>5-FU</td>
<td>+</td>
</tr>
<tr>
<td>SN38</td>
<td>-</td>
<td>SN38</td>
<td>-</td>
</tr>
</tbody>
</table>

+/− SART1 siRNA

SART1
PARP
GAPDH

B

HCT116

% Cell death

SC
SART siRNA

C

RKO

% apoptosis

SC
SART1 siRNA

D

LS174T

% Cell death

SC
SART siRNA
Figure 5

A

SART1 72h SN38 HCT

- 0.5 mM SART1
- 1 mM SART1
- 5 mM SART1

B

SART1 72h 5-FU HCT

- 0.5 mM SART1
- 1 mM SART1
- 5 mM SART1

C

SART1 72h SN38 LS174T

- 0.5 mM SART1
- 1 mM SART1
- 5 mM SART1

D

SART1 72h 5-FU LS174T

- 0.5 mM SART1
- 1 mM SART1
- 5 mM SART1

E

SART1 72h SN38 RKO

- 0.5 mM SART1
- 1 mM SART1
- 5 mM SART1

F

SART1 72h 5-FU RKO

- 0.5 mM SART1
- 1 mM SART1
- 5 mM SART1
Figure 6

A

% Apoptosis

SC

1nM SART1

Con 5-FU SKB8 Con 2nd 5-FU 2nd SN38 2nd

B

% Apoptosis

SC SART1 siRNA C8 siRNA C8 + SART1 siRNA

24h 48h

C

C8 RLU

SC C8 SART1 C8+SART1

24h 48h

D

C37 RLU

SC C8 SART1 C8+SART1

24h 48h

D

SART1

PARP

Procaspsase 8

FLIP

GAPDH

E

% apoptosis

SC SIS1

HCT16 FL17 FL24

*** ***
Molecular Cancer Therapeutics

A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer


Mol Cancer Ther Published OnlineFirst October 25, 2011.

Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-11-0510

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2011/10/18/1535-7163.MCT-11-0510.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.